Director · Apimeds Pharmaceuticals US, Inc. · Apimeds Pharmaceuticals US, Inc. — Stock Option (right to buy)
Side
A
Value
—
Shares
10.0K
Price
—
Executed
Nov 11, 2025
Disclosed
Nov 13, 2025
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Nov 11 executedNov 13, 2025 disclosed
APUS · daily
Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Grant or award — administrative, little informational value
Relative size+1 / 25
No reported dollar value · new position
Filing timing0 / 15
Disclosed 2 business days after execution (deadline: 2)
Historical behavior+8 / 15
First recorded trade by this actor in this security
Frequency & clustering0 / 15
No clustered activity in the dataset
Market events0 / 10
No material company filing within 60 days after the trade
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
Apimeds Pharmaceuticals US, Inc. — Stock Option (right to buy)
Ticker
APUS
Shares
10.0K
Price per share
$0
Execution date (reported)
Nov 11, 2025
Owned after transaction
10.0K shares
Days from execution to publication
2
What this establishes
Weintraub Bennett filed this Form 4 reporting a grant or award of APUS on Nov 11, 2025. It became public on Nov 13, 2025. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
Director
Weintraub Bennettcik:0002040378
Issuer
Apimeds Pharmaceuticals US, Inc.cik:0001894525
Revision history · 0
No field has changed since this record was first ingested.
